and/or the Digestive Disease Week meeting. These meetings will take
place in April and May, respectively.
-- The company expects to initiate its 14-day triple combination study of
ITMN-191 in combination with Pegasys(R) and ribavirin, in the second
quarter of 2008. The study design and timeline will be shared at study
-- An Investigational New Drug (IND) application is expected to be filed
by Roche for ITMN-191/R7227 in the second half of 2008 to gain FDA
approval to study the compound in the United States.
Conference Call and Webcast Details
InterMune will host a conference call today at 4:30 p.m. EST to discuss its financial results for the fourth quarter and full year 2007, its forward-looking financial guidance and its clinical development programs. Interested investors and others may participate in the conference call by dialing 888-799-0528 (U.S.) or 706-634-0154 (international), conference ID# 32601453. A replay of the webcast and teleconference will be available approximately three hours after the call.
To access the webcast, please log on to the company's website at http://www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 32601453. The webcast will remain available on the company's website until the next earnings call.
InterMune is a biotechnology company focused on the research,
development and commercialization of innovative therapies in pulmonology
and hepatology. InterMune has a pipeline portfolio addressing idiopathic
pulmonary fibrosis (I
|SOURCE InterMune, Inc.|
Copyright©2008 PR Newswire.
All rights reserved